Teduglutide, known also for its medicine names Gattex/ALX 0600, is primarily utilized for the treatment of short bowel syndrome (commonly abbreviated SBS).

The disease is generally due to a series of syndromes caused by a serious intestinal disease or the surgical removal of most small intestines. People with SBS cannot absorb enough water, vitamins, and other nutrients from food to sustain life. The treatment options are complex and varied as well. Clinical trials have shown that the teduglutide is capable of reducing certain demands of short bowel syndrome patients towards parenteral nutrition, which is currently the first non-surgical treatment for SBS.

In particular, teduglutide, as the glucagon-like peptide-2 (GLP-2) analogue, is a protein related to gut’s growth and functions. It works by promoting mucosal growth and possibly restoring gastric emptying and secretion and can be used as the targeted therapy in SBS. In addition to the existing cumbersome intravenous administration with parenteral nutrition, teduglutide can also be another choice for mass researchers.

Source: http://www.localnews.biz/news_83662.asp